Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Brexpiprazole LAI in Schizophrenia
NCT02968121Phase 1Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brexpiprazole in schizophrenia (5 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Change in Suicidality via Columbia-Suicide Severity Rating Scale, Number of reported Adverse Events (AE) at 182 days and 7 more. Started Jan 2017; status: terminated.
02
Drugs
brexpiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02968121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968121.